– Cambridge Allergy Ltd (“Camallergy” or “the Company”), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.
– The £1.1M in non-dilutive funding will be used to accelerate the Company’s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials.
– The project commences in the first quarter of 2021, and as part of the project’s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.

– CN Bio announced a grant from Innovate UK to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
– The funding will be used to develop and test advanced cell culture models that represent different regions of the lung and subsequently linking these models to other organ systems, such as liver and gut, to inform the rapid development of novel therapeutics.
– The fast-moving nature of the COVID-19 pandemic directs additional pressure onto current drug discovery and development processes, which can be limited by misrepresentative in vivo models that cause a large proportion of new medicines to fail when taken to clinical trials.
– To circumvent this, CN Bio is developing single and multi-organ COVID-19 models to investigate virology and immunology throughout the body, with a prolonged viable cell culture time for extended studies.